© 2020 MJH Life Sciences and Psychiatric Times. All rights reserved.
© 2020 MJH Life Sciences™ and Psychiatric Times. All rights reserved.
November 24, 2020
Joining together to discuss psychosis, 3 British experts discuss various ways to respond to and help people who have experienced both trauma and psychosis.
November 20, 2020
A recent drug trial yields encouraging results.
November 19, 2020
COVID-19 has made treating patients who receive long-acting injectables complicated. The Chief Medical Officer of Houston Behavioral Healthcare Hospital offers suggestions on how best to proceed.
Recent research sheds light on the role of adjunctive long-acting injectable antipsychotics in treatment-resistant schizophrenia.
November 18, 2020
ALKS 3831, if approved by the FDA, could be a promising new treatment option for schizophrenia or bipolar I disorder.
Manufacturing issues stall progress with ALKS 3831, Alkermes’s promising new drug for the treatment of schizophrenia and bipolar I disorder.
November 16, 2020
New research underlies the need for addressing identity in young patients during early stages of psychosis.
November 13, 2020
An explanation for the clinical presentation of delusions and hallucinations may have just been found.
More than 50% of patients with schizophrenia are estimated to be nonadherent with their antipsychotic medication regimen. What treatment solutions are available?
November 06, 2020
Data from a randomized phase III trial shows promise for new treatment strategy.